background: the use of thrombolytic agents in the treatment of hemodynamically stable patients with acute submassive pulmonary embolism (pte) remains controversial. we, therefore, conducted this study to compare the effect of thrombolytic plus anticoagulation versus anticoagulation alone on early death and adverse outcome following submassive pte. methods: w e conducted a study of patients with...

In massive pulmonary embolism where there may be evidence of right ventricular dysfunction and acute pulmonary hypertension, anticoagulation therapy alone may prove inadequate. In such situations use of thrombolytic agents produces an improvement in haemodynamics compared to anticoagulants alone, although studies to date have been too small to address the issue of mortality benefit. It would ap...

background thrombolytic therapy in patients with sub-massive pulmonary embolism (smpte) needs further assessment. objectives the current study aimed to assess a potential benefit of thrombolytic and non-thrombolytic therapy in patients with smpte. patients and methods one hundred-nineteen patients were enrolled with smpte from 2006 to 2010 in the tertiary care center of rajaie medical and resea...

IMPORTANCE Thrombolytic therapy may be beneficial in the treatment of some patients with pulmonary embolism. To date, no analysis has had adequate statistical power to determine whether thrombolytic therapy is associated with improved survival, compared with conventional anticoagulation. OBJECTIVE To determine mortality benefits and bleeding risks associated with thrombolytic therapy compared...

PURPOSE OF REVIEW Pulmonary embolism remains one of the leading causes of cardiovascular mortality. The wide range of reported mortality rates reflects heterogeneity in comorbidity and severity of pulmonary embolism. Optimizing risk stratification to prognose pulmonary embolism patients appears to be important to improve management, treatment and clinical outcome. RECENT FINDINGS Hemodynamic ...

A NATIONAL INSTITUTES OF HEALTH Consensus Development Conference, held at NIH April 10-12, 1980, addressed the issue of thrombolytic therapy* for the management of acute deep-vein thrombosis and pulmonary embolism. At NIH, consensus development conferences bring together biomedical research scientists, practicing physicians, consumers, and others as appropriate in an effort to reach general agr...

We report on the 2008 update of Guidelines on the diagnosis and management of acute pulmonary embolism (PE) of the European Society of Cardiology that have been endorsed and recommended by the Croatian Cardiac Society. The guidelines focus on currently available and validated methods of diagnosis, prognostic assessment (prediction of outcome and death risk), treatment of pulmonary embolism and ...

BACKGROUND Randomized trials and meta-analyses have reached conflicting conclusions about the role of thrombolytic therapy for the treatment of acute pulmonary embolism. METHODS AND RESULTS We performed a meta-analysis of all randomized trials comparing thrombolytic therapy with heparin in patients with acute pulmonary embolism. Eleven trials, involving 748 patients, were included. Compared w...

Anticoagulation therapy is mandatory in patients with pulmonary embolism to prevent significant morbidity and mortality. The mainstay of therapy has been vitamin-K antagonist therapy bridged with parenteral anticoagulants. The recent approval of new oral anticoagulants (NOACs: apixaban, dabigatran, and rivaroxaban) has generated significant interest in their role in managing venous thromboembol...

Untreated massive pulmonary embolism is associated with a high mortality. Pulmonary embolectomy has been largely superceded by thrombolytic therapy, but there are cases in which pulmonary embolectomy remains the treatment of choice. We present three case reports and discuss the merits of the various treatments available for massive pulmonary embolism. The primary treatment of massive pulmonary ...